RxDoctor Payments Data

Alan Gabbard, MD

Gastroenterology · Springfield, OHNPI 1518965896

Payments from drug & device makers

$1,282in general payments, 2019–2025

Across 31 payments — averaging $41.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$292
  • Ipsen Biopharmaceuticals, Inc$150
  • Boston Scientific$134
  • Sanofi$134
  • E.r. Squibb & Sons, L.L.C.$125
  • Braintree Laboratories, Inc.$116
  • plus $332 from 8 others

What the payments were for

  • Food & beverage$1,14689%
  • Education$302%
  • Gifts$1078%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,282 in reported general payments places this provider in the 35th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$67,627
Medicare patients
285
Services billed
554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin23$72,462
CreonLipase/Protease/Amylase11$24,275
Mesalamine34$15,235
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C51$6,739
LinzessLinaclotide12$6,532
Ursodiol29$4,912
Balsalazide Disodium26$4,857
Dexlansoprazole DrDexlansoprazole17$4,671
Mercaptopurine11$2,964
Omeprazole159$1,978
Pantoprazole Sodium141$1,872
Dicyclomine Hcl84$1,632
CholestyramineCholestyramine (With Sugar)13$763
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine22$740
Tenofovir Disoproxil Fumarate16$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$11$79,20174 claims
AbbVieCreon, Linzess$292$30,80723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →